ERBB2 and cancer: Trastuzumab deruxtecan consists of a humanized anti-HER2 monoclonal antibody, a cleavable tetrapeptide base linker, and a cytotoxic topoisomerase I inhibitor that prevents cancer cells from replicating DNA, leading to cancer cell death (Indini et al., 2021) (Table 1).